Interaction Checker
Potential Interaction
Cabotegravir/rilpivirine [long acting] (CAB/RPV LA)
Escitalopram
Quality of Evidence: Very Low
Summary:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with escitalopram. However, given the known QT prolongation risk associated with escitalopram, caution is recommended
Description:
View all available interactions with Cabotegravir/rilpivirine [long acting] (CAB/RPV LA) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.